Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
Alternativ können Sie versuchen, selbst über Ihren lokalen Bibliothekskatalog auf das gewünschte Dokument zuzugreifen.
Bei Zugriffsproblemen kontaktieren Sie uns gern.
4 Ergebnisse
Sortierung:
In: Impact, studies in language and society v. 8
Many of the assumptions of Labovian sociolinguistics are based on results drawn from US and UK English, Latin American Spanish and Canadian French. Sociolinguistic variation in the French of France has been rather little studied compared to these languages. This volume is the first examination and exploration of variation in French that studies in a unified way the levels of phonology, grammar and lexis using quantitative methods. One of its aims is to establish whether the patterns of variation that have been reported in French conform to those reported in other languages. A second important
In: Buksnys , T , Armstrong , N , Worthy , G , Sabatschus , I , Boesl , I , Buchheister , B , Swift , S L , Noake , C , Carrera , V H , Ryder , S , Shah , D , Liedgens , H & Kleijnen , J 2020 , ' Systematic review and network meta-analysis of the efficacy and safety of lidocaine 700 mg medicated plaster vs. pregabalin ' , Current Medical Research and Opinion , vol. 36 , no. 1 , pp. 101-115 . https://doi.org/10.1080/03007995.2019.1662687
Objective: Neuropathic pain prevalence is estimated between 7% and 10% of the population. International guidelines recommend a variety of drugs at different therapy lines for pain relief. However, side effect profiles, for example, prompted the UK government recently to classify pregabalin and gabapentin as class C drugs. Lidocaine 700 mg medicated plaster (LMP) might be a safer alternative. A systematic review assessed how LMP and pregabalin compared in terms of efficacy and safety. The review focused on pain reduction, quality of life and adverse events in peripheral neuropathic pain (PNP) i.e. post-herpetic neuralgia, diabetic peripheral neuropathy, post-surgical/trauma, or other PNP conditions. Methods: Electronic databases were searched as well as a number of other sources up to November 2018. Sensitive strategies were used, with no restriction by language or publication status. Two independent reviewers screened records and extracted data with consensus determining final decisions. Risk of bias was assessed using the Cochrane Collaboration 2011 checklist for RCTs. Full network meta-analysis was conducted to compare LMP to pregabalin 300/600 mg in terms of pain reduction, quality of life, as well as serious adverse events and selected adverse events. Trials with enriched enrolment design were excluded. Results: Searches retrieved 7,104 records. In total 111 references pertaining to 43 RCTs were included for data extraction. Bayesian network meta-analysis of several pain outcomes showed no clear difference in efficacy between treatments However, LMP was clearly advantageous in terms of dizziness and any adverse event vs. pregabalin 600 mg/day and discontinuations vs. pregabalin 300 mg/day or 600 mg/day, as well as being associated with improved quality of life (albeit in this case based on weak evidence). Conclusions: LMP was found to be similar to pregabalin in reducing pain in all populations but had a better adverse events profile.
BASE